Free tool
Cell therapy stocks
We cover 5 companies grouped under the Cell therapy theme. The median market value in the group is $2.25B. Across the group, the median move over the past trading day is +2.17%. Price change over the past year runs from −24.6% to +148.5% across the middle 80 percent of the group, with a median of +9.4%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
5 of 86 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| LEGN | Legend Biotech Corporation | $21.30 | +10.53% | −0.98% | −38.44% |
| IOVA | Iovance Biotherapeutics, Inc. | $8.44 | +72.24% | +234.92% | +233.60% |
| MSB.AX | Mesoblast Limited | 2.40 AUD | +16.26% | −13.54% | −3.82% |
| MESO | Mesoblast Limited | $17.19 | +18.06% | −5.34% | +9.42% |
| VCEL | Vericel Corporation | $43.22 | −4.63% | +21.37% | +20.76% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.